Navigation Links
New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
Date:6/5/2011

INDIANAPOLIS, June 5, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening, for patients with a specific type of lung cancer called advanced nonsquamous non-small cell lung cancer (NSCLC).

"Continuation maintenance" treatment is when one of the same medicines used in first-line treatment setting is continued as maintenance therapy in an effort to control the cancer.  

Results from the study will be presented on Sunday, June 5 at 11:30 a.m. CDT during the Lung Cancer Oral Abstract Session (Abstract #CRA7510) at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill.  Lilly will present overall survival results from PARAMOUNT at a medical meeting in the future.

PARAMOUNT is the second study to evaluate the use of ALIMTA as a maintenance therapy in patients with advanced nonsquamous NSCLC, and the first study to evaluate the use of continuation maintenance with ALIMTA(1) following first-line ALIMTA plus cisplatin therapy.

Results of this multicenter, double-blind trial demonstrated the median progression-free survival measured from randomization (after first-line treatment) was 3.9 months on the ALIMTA arm as compared to 2.6 months on the placebo arm with a hazard ratio of 0.64.  Said another way, the study showed that ALIMTA continuation maintenance arm resulted in a 36 percent improvement of survival without disease worsening over the placebo arm. The maintenance disease control rate, or the percentage of patients achieving either a response or stable disease first measured at 6 weeks post-randomization was 71.8 percent (2.8%/69.0%) on the ALIMTA
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
2. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
3. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
4. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
5. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
6. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
7. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
8. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
9. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
10. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
11. U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Pete Rose, baseball,s all-time hits leader, is the ... reliever Myoflex, Ducere Pharma has announced. "Pete,s a ... to have him on board with Myoflex," said Ducere Pharma ... legendary player who is known across all generations. The passion ...
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), ... equipment for all forms of sports, including extreme motor ... brace, announced today that the UISP Lega Motociclismo Lombardia, ... all riders to wear a neck brace during its ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... the Barbara,Ann Karmanos Cancer Institute and Wayne State ... vaccine that has shown to be effective on ... in the September 15 issue,of Cancer Research, a ... ( http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELO ,GO), Wei-Zen Wei, Ph.D., professor ...
... Screening May Not Be Necessary For Diabetic Patients, ... Type 2 diabetes in the United States alone. Coronary ... patients with diabetes.,Silent myocardial ischemia is common, and cardiac ... CAD., Data from the Detection of Ischemia in ...
Cached Medicine Technology:DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers 2Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study 2
(Date:1/22/2015)... Bradley, Illinois (PRWEB) January 22, 2015 Deer ... -- will host a Valentine’s Day Happy Hour from 3 p.m. ... located at 12500 Regency Parkway in Huntley, Illinois, serves adults with ... Happy Hour event will include Valentine's Day treats, games and sweetheart-themed ...
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... Pharmacologic Agent Developed for the Treatment of Premature ... ... Janssen-Cilag companies in,Europe have submitted a Marketing Authorisation Application (MAA) for,dapoxetine, ... Premature ejaculation is a form of male sexual dysfunction associated,with ...
... time, review shows , , FRIDAY, Dec. 7 (HealthDay News) -- The ... of death, from suicide as well as other causes, a new ... days following the loss. , More research needs to be done ... according to the article in the Dec. 8 issue of ...
... PRINCETON, N.J., Dec. 7 Medarex, Inc.,(Nasdaq: ... an undisclosed,milestone payment from its licensing partner, Centocor, ... of ustekinumab,(CNTO 1275) in the United States and ... severe plaque psoriasis by Centocor., Ustekinumab is ...
... CNN Worldwide and its global audience,paid special tribute tonight ... as "CNN Heroes" in a global telecast.,CNN,s Anderson Cooper ... the American Museum of Natural History in New York,City., ... initiative has shone a,spotlight upon dozens of amazing people ...
... Mass., Dec. 6 Inverness Medical,Innovations, Inc. (Amex: ... of rapid,diagnostic products for the consumer and professional ... 2007 RBC Capital Markets Healthcare,Conference being held December ... City. Ron Zwanziger, Chief Executive Officer, and Jon ...
... Dec. 6 A gene related to rapid replication ... to contain some identical,protein sequences in, tobacco mosaic virus ... for cancer, the AMAS(R) test, appears,to measure this gene,s ... of reports on the use of a new,methodology to ...
Cached Medicine News:Health News:Submission of Marketing Authorisation Application for Dapoxetine in Europe 2Health News:Mourning Death of Loved One Raises Your Risk of Dying 2Health News:Mourning Death of Loved One Raises Your Risk of Dying 3Health News:Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis 2Health News:Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis 3Health News:CNN Honors Extraordinary Deeds of Seven Everyday People in Global Event 2Health News:CNN Honors Extraordinary Deeds of Seven Everyday People in Global Event 3Health News:CNN Honors Extraordinary Deeds of Seven Everyday People in Global Event 4Health News:Inverness Medical Innovations to Participate at 2007 RBC Healthcare Conference on December 12, 2007 2Health News:AMAS Test Measures Lethal Replikin Gene Activity in Lung and Other Cancers 2Health News:AMAS Test Measures Lethal Replikin Gene Activity in Lung and Other Cancers 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: